Publications
Azadeh Akhavanallaf, Zhonglin Lu, Avery B Peterson, Johan Blakkisrud, Sara Kurkowska, Surekha Yadav, Chang Wang, Carlos Uribe, Caroline Stokke, Arman Rahmim, Ka Kit Wong, Jean-Mathieu Beauregard, Thomas a Hope, Katarina Sjögreen Gleisner, Yuni K Dewaraja
(2025).
Can 177Lu-DOTATATE Kidney Absorbed Doses be Predicted from Pretherapy SSTR PET? Findings from Multicenter Data.
J Nucl Med.
Johannes Tran-Gia, Francesco Cicone, Michel Koole, Francesco Giammarile, Jonathan Gear, Emmanuel Deshayes, Pablo Minguez Gabiña, Marta Cremonesi, Jonathan Wadsley, Peter Bernhardt, Manuel Bardiès, Silvano Gnesin, Mattias Sandström, Ulrike Garske-Román, Mona-Elisabeth R Revheim, Frederik a Verburg, Mark Konijnenberg, Bernd Joachim Krause, Michael Lassmann, Caroline Stokke
(2025).
Rethinking Dosimetry: A European Perspective.
J Nucl Med.
Kjetil Berner, Eivor Hernes, Monika Kvassheim, Mona-Elisabeth Revheim, Julie Bastiansen, Silje Selboe, Charlotte L Bakken, Simen R Grønningsæter, Øyvind S Bruland, Roy H Larsen, Lily Bouzelmat, Vicki L Jardine, Caroline Stokke
(2025).
First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen-Targeted 212Pb Radioligand, in Patients with Metastatic Castration-Resistant Prostate Cancer.
J Nucl Med.
Bendik S Abrahamsen, Torgrim Tandstad, Bjørg Y Aksnessæther, Trond v Bogsrud, Miguel Castillejo, Eivor Hernes, Håkon Johansen, Thomas M I Keil, Ingerid S Knudtsen, Sverre Langørgen, Kirsten M Selnæs, Tone F Bathen, Mattijs Elschot
(2025).
Added Value of [18F]PSMA-1007 PET/CT and PET/MRI in Patients With Biochemically Recurrent Prostate Cancer: Impact on Detection Rates and Clinical Management.
J Magn Reson Imaging.
Solfrid Thunold, Eivor Hernes, Saima Farooqi, Åsa Kristina Öjlert, Roslyn J Francis, Anna K Nowak, Weronika Maria Szejniuk, Søren Steen Nielsen, Susana Cedres, Marc Simo Perdigo, Jens Benn Sørensen, Carin Meltzer, Lars Tore Gyland Mikalsen, Åslaug Helland, Eirik Malinen, Vilde Drageset Haakensen
(2025).
Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccine.
Eur J Nucl Med Mol Imaging.